A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-10. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
SR-15099, also known as SR 2.0, is an atypical opioid and close analogue of SR-17018 and brorphine. It is the analogue of SR-17018 in which the chlorine atom on the benzyl ring has been replaced with a bromine atom. The drug is a non-competitive partial biased agonist of the μ-opioid receptor (MOR) similarly to SR-17018. It has similar effects in animals as SR-17018, such as having robust analgesic effects but producing minimal respiratory depression or hyperlocomotion. SR-15099 was first described in the scientific literature by Laura M. Bohn and colleagues by 2017.
In August 2016, Biden visited Serbia, where he met with the Serbian Prime Minister Aleksandar Vučić and expressed condolences for civilian victims of the bombing campaign during the Kosovo War. Biden never cast a tie-breaking vote in the Senate, making him the longest-serving vice president with this distinction. During his second term, Biden was often said to be preparing for a bid for the 2016 Democratic presidential nomination. With his family, friends, and donors encouraging him in mid-2015 to enter the race, and with Hillary Clinton's favorability ratings in decline at that time, Biden was reported to be seriously considering the prospect and a "Draft Biden 2016" Political action committee (PAC) was established. During 2015, Biden was uncertain about running, particularly due to the recent death of his son Beau, before announcing his decision not to run that October.
Orlistat is a lipase inhibitor which prevents the absorption of fats after meals. It is approved in children 12 years and older, but use is often limited due to adverse reactions of bowel urgency, fecal incontinence, flatulence and it may cause deficiencies in fat-soluble vitamins. Phentermine is an amphetamine analogue which is used as an appetite suppressant; it may be used for up to 12 weeks at a time in adolescents 16 years and older. Possible adverse reactions include headache, nausea, palpitations, elevations in blood pressure, restlessness or insomnia. Phentermine is also available in combination with topiramate extended release and the combination is approved for use in adolescents 12 years and older. Topiramate is an anticonvulsant, but has been shown to cause weight loss. Phentermine-topiramate XR has similar possible side effects to phentermine and users should be on contraception due to the risk of teratogenic effects of the medication. Liraglutide and semaglutide are glucagon-like peptide-1 receptor agonists which are approved for the treatment of obesity in adolescents 12 years and older. Liraglutide is a once-daily injection and semaglutide is a once-weekly injection. They are thought to work by delaying gastric emptying, decreasing appetite and increasing satiety. Possible side effects of liraglutide or semaglutide include gastrointestinal distress including nausea, vomiting, diarrhea or constipation, abdominal discomfort or indigestion.
Sources: en.wikipedia.org
Lysine malonylation (Kmal, maK), protein malonylation or malonylation, is a reversible post-translational modification (PTM) in eukaryotic and prokaryotic cells, in which a malonyl group (–CO–CH2–COOH) is added to a lysine (K) residue of a protein. It was first identified in 2011 by Peng et al. as an evolutionarily conserved modification and belongs to the acidic acyl modifications such as succinylation and glutarylation. As a dynamically regulated modification, it responds to conditions such as stress responses, metabolic processes, and mutations, thereby influencing the charge, structure, and function of proteins. This involves, among other things, the metabolic pathways of glucose and fatty acids as well as histone-mediated gene regulation, and is increasingly associated with immune regulation, angiogenesis, osteoarthritis, cancer and metabolic diseases such as obesity and type 2 diabetes. Its biological significance is increasingly recognized, but many aspects of its regulation and function remain unresolved, so that its therapeutic potential is still unexplored.
A major target of poaching is the totoaba in the Gulf of California, due to its perceived similarity to the traditional high-grade swim bladder of Bahaba taipingensis. The totoaba, a critically endangered species, is protected by CITES. Poachers use gillnets to capture the totoaba, and often remove the valuable bladder and toss the dead fish into the sea to minimize evidence. Poaching operations were backed by a transnational organized crime ring known by the moniker 'the Dragon Cartel' (Spanish: Cártel del Dragón): a cooperation between Chinese organized crime and Mexican cartels, particularly the Sinaloa cartel, operating in Mexicali, Baja California. Mexican cartels poached totoaba maw (Spanish: buches) and smuggled them through local restaurateurs to international ports like Vancouver, and traded them with Chinese criminals for the chemical precursors to fentanyl. As of 2021, a single totoaba maw sold for US$3-5,000 equivalent in Mexico, US$10-15,000 in the US, and US$60,000 in China. For its high price and involvement with drug trafficking, totoaba maw has been given the media moniker "cocaine of the sea". In 2019, internal documents of the Secretariat of Environment and Natural Resources (SEMARNAT) of Mexico claimed that the government has minimally investigated cartel activity. SEMARNAT's prosecution branch PROFEPA opened 42 investigations into totoaba poaching between 2012 and 2021, resulting in two arrests.
=== Extraction methods === Ossein can be isolated by treating bones with hydrochloric acid, which dissolves the inorganic matrix (calcium phosphate and calcium carbonate). The process was discovered no later than 15th century but only really spread in the 18th century, after Glauber's publications. The resulting liquor carrying calcium chloride and phosphoric acid may then be treated with calcium hydroxide to recover dicalcium phosphate for fertilizers or animal feed supplement. However, the most popular technique of treating the bone meal is steaming or boiling. This process requires no acid but much more energy and may also produce tricalcium phosphate. As an alternative, the deproteinized bone residue left after the removal of ossein can be used to produce bone ash for the manufacture of bone china.
Sources: en.wikipedia.org
=== Silicone oil leakage === Silicone oil is the common fluid that is used to heat or cool shelves in the freeze-dryer. The continuous heat/cool cycle can lead to a leakage of silicone oil at weak areas that connect the shelf and hose. This can contaminate the product leading to major losses of pharmaceuticals and food products. Hence, to avoid this issue, mass spectrometers are used to identify vapors released by silicone oil to immediately take corrective action and prevent contamination of the product.
== History == Athletes in ancient Greece were advised to consume large quantities of meat and wine. A number of herbal concoctions and tonics have been used by strong men and athletes since ancient times across cultures to try to increase their strength and stamina. In the 1910s, Eugen Sandow, widely considered to be the first modern bodybuilder in the West, advocated the use of dietary control to enhance muscle growth. Later, bodybuilder Earle Liederman advocated the use of "beef juice" or "beef extract" (basically, consommé) as a way to enhance muscle recovery. In the 1950s, with recreational and competitive bodybuilding becoming increasingly popular, Irvin P. Johnson began to popularize and market egg-based protein powders marketed specifically at bodybuilders and physical athletes. The 1970s and 1980s marked a dramatic increase in the growth of the bodybuilding supplement industry, fueled by the widespread use of modern marketing techniques and a marked increase in recreational bodybuilding. In October 1994, the Dietary Supplement Health and Education Act (DSHEA) was signed into law in the USA. Under DSHEA, responsibility for determining the safety of the dietary supplements changed from the government to the manufacturer, and supplements no longer required approval from the U.S. Food and Drug Administration (FDA) before distributing the products. Since that time, manufacturers did not have to provide FDA with the evidence to substantiate safety or effectiveness unless a new dietary ingredient was added.
==== Albums ==== Opus (Opus album), 1987, by Austrian band Opus Opus (Schiller album), 2013, by German music project Schiller Opus, 2014, by Jane Badler Opus (Eric Prydz album), 2016, by the electronic artist Eric Prydz "Opus" (Eric Prydz song), song from the eponymous album Opus, a 2007 compilation album by Mr. Sam Opus (Marc Anthony album), 2019, by Puerto Rican singer Marc Anthony
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.